JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4489 TC-A 2317 hydrochloride

Target: Aurora Kinases

Summary: Aurora kinase A inhibitor,potent and selective

<39.29 mg/mL
A1821 Ki8751

Target: VEGFR

Summary: VEGFR-2 inhibitor,potent and selective

≥23.45 mg/mL
A5112 XL147

Target: PI3K

Summary: PI3K inhibitor,selective and reversible

≥22.45 mg/mL
A5166 Ondansetron HCl

Target: 5-HT3 Receptors

Summary: 5-HT3 receptor antagonist

insoluble in EtOH; insoluble in H2O; ≥33.04 mg/mL
A8307 Crenolanib (CP-868596)
1 Citation

Target: FLT3|PDGFR

Summary: PDGFR-β inhibitor,potent and selective

≥22.2 mg/mL
A8336 KU-60019
2 Citation

Target: ATM/ATR

Summary: ATM kinase inhibitor,potent and selective

≥27.4 mg/mL
A8557 TAE226 (NVP-TAE226)
1 Citation

Target: FAK

Summary: FAK inhibitor,potent and ATP-competitive

≥23.45 mg/mL
B1642 WYE-125132 (WYE-132)

Target: mTOR

Summary: ATP-competitive mTOR inhibitor, highly potent

insoluble in EtOH; insoluble in H2O; ≥13 mg/mL
B4899 BLZ945
1 Citation

Target: CSF-1R

Summary: CSF-1R kinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.9 mg/mL
B4900 Indoximod (NLG-8189)

Summary: Indoleamine 2,3-dioxygenase (IDO) pathway inhibitor

insoluble in DMSO; insoluble in EtOH; ≥1.12 mg/mL